Cramer is at it again, cheer leading this dog, which has disappointed quarter after quarter. These depleted oil wells that they bought from Exxon, saying they were smarter than Exxon, are producing a lot of water, so much water that it has become disruptive. I think there is more disappointment to come. When you are not making money, and you have pilled up as much debt as these guys have for something that is not working, dividend would be eliminated before long.
These people thought and told us they are smater than Exxon, wrong, they bought Exxon's throwaway, and now they are finding out they were wrong.
Tired of this man padding himself in back and telling how great they done, while running this company to ground. He is picking up what others want to throw away, and claims he can do better with the asets, well he is wrong, the joke has been on him. Sold the shares.
This disease kills 48000 people in US alone, more than breast cancer, the pts population in US is 128000.
The drug price is at $42,000 in Canada and Europe. I think Goldman downgraded the stock to neutral to prevent it from going up too much to spoil the deal.
I think rate of uptake will be considerably different in US than elsewhere. Read the online posts by pts from Canada, they are fuming with anger that their provinces do not cover the drug. In US insurance companies don't tell pts they will not pay because it costs $40,000 a year.
What puzzles me this morning is Goldman downgrading of the stock, I wonder what their policy is with analysts, if their bank side is helping the company with a sale.
There are 128,000 patients in US alone. Company has priced the drug at $42000 per year in Canada and Europe. If they were to price it the same in US, which would be a conservative assumption, and if 100,000 people went on the drug, that would be whopping $4.2 Billion sales in US alone, at 5 times the sales just on US sales that would give it a value of over $20 Billion, or $500 per share. can someone tell me where I am wrong? One thing puzzles me though, when you Google, there are generic offering of this drug from online pharmacies, how is that possible?
I think Obama is paying more attention to Africa, and his US attorney being African American, may have something to do here, they are trying to do their part to fix things in Africa, but I guess they do not understand the culture.
Company were assigned 2 companies as part of the contractor group. Allegations has been made that a senior Angolan government officials had interest in one of these contractors ( source 2013, 10K. Company claims that they did not know this company well, therefore they were not aware of the official interest.
From what I understand, in that part of the world, this is how cookie crumbles. The question is what is at stake for shareholders. From my point of view, you need to do a search on background of the companies you deal with, but is this sort of thing that is a routine practice in Angola, are the others doing it as well. This is important, I think CIE can easily handle the SEC fines, but what are the consequences in Angola, I suspect nothing, corruption is perhaps the way of the life, and expected there.
Watch the opening, and see where it goes from there. This thing about Inversion, is for birds. Congress is in control of republicans, they will not go along with any legislation with government controls. Instead they will point, as they have in the past that lower corp. tax rate is the answer.
Insurance companies still cover drugs that are not in formulary, but copay is higher. So companies poorly worded press release that 20 to 30% is affected, does not mean they are going to lose 20-30 sales. affect on sales depends how bad the patients want the drug, and if they are willing to pay the higher copay.
I am not worried about inversion bill. Republicans will use this to push for lowering taxes on corporations, which is a double taxation on investors.
This sort of thing happen, but press release is making it worse. Investors would want to know what they will do so that this does not happen with others, and what they are going to do to get back on the formulary, was it a price issue, why they took them out?
Don't be fooled by headlines, revenue beat estimates, and earning EX one time items was 41 cents VS estimates of 29 Cents.
ENTA has very low market cap, and very rich pipeline in very hot areas. The analyst thinks because Abive is buying Shire they will not buy ENTA any more. Wrong, ENTA will be a small acquisition even at 100% premium. If economically makes sense , then Abive will buy, and it sure does make sense for Avive to buy this incredible value Biotech.
Surely they would not owned that many share if conclusion such as contributor to SA could be reached with publicly available data could be reached, Fidelity would not have this many shares.